Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey
Access to bevacizumab, an important component of oncology treatment regimens, may be limited. This survey of oncologists in the US (n = 150), Europe (n = 230), and emerging markets (EM: Brazil, Mexico, and Turkey; n = 130) examined use of and barriers to accessing bevacizumab as treatment of advance...
| Main Authors: | , , , |
|---|---|
| Other Authors: | |
| Language: | en |
| Published: |
MDPI AG
2017
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10150/625838 http://arizona.openrepository.com/arizona/handle/10150/625838 |